




ATLAS OF GENODERMATOSES

SECOND EDITION

Gianluca Tadini

Michela Brena • Carlo Gelmetti • Lidia Pezzani



ATLAS OF GENODERMATOSES

SECOND EDITION

Gianluca Tadini, MD

Pediatric Dermatology Unit and Pediatric Clinic 1, Department of Pathophysiology and Transplantation, Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, University of Milan, Milan, Italy

Michela Brena, MD

Post-Graduate School of Dermatology and Venereology,
University of Milan, Milan, Italy

Carlo Gelmetti, MD

Chairman of Pediatric Dermatology Unit, Department of Pathophysiology and Transplantation, Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, University of Milan, Milan, Italy

Lidia Pezzani, MD

Post-Graduate School of Medical Genetics,
University of Milan, Milan, Italy



CRC Press

Taylor & Francis Group
Boca Raton London New York

CRC Press is an imprint of the
Taylor & Francis Group, an **informa** business

CRC Press
Taylor & Francis Group
6000 Broken Sound Parkway NW, Suite 300
Boca Raton, FL 33487-2742

© 2015 by Taylor & Francis Group, LLC
CRC Press is an imprint of Taylor & Francis Group, an Informa business

No claim to original U.S. Government works
Version Date: 20150304

International Standard Book Number-13: 978-1-4665-9836-2 (eBook - PDF)

This book contains information obtained from authentic and highly regarded sources. While all reasonable efforts have been made to publish reliable data and information, neither the author[s] nor the publisher can accept any legal responsibility or liability for any errors or omissions that may be made. The publishers wish to make clear that any views or opinions expressed in this book by individual editors, authors or contributors are personal to them and do not necessarily reflect the views/opinions of the publishers. The information or guidance contained in this book is intended for use by medical, scientific or health-care professionals and is provided strictly as a supplement to the medical or other professional's own judgement, their knowledge of the patient's medical history, relevant manufacturer's instructions and the appropriate best practice guidelines. Because of the rapid advances in medical science, any information or advice on dosages, procedures or diagnoses should be independently verified. The reader is strongly urged to consult the relevant national drug formulary and the drug companies' and device or material manufacturers' printed instructions, and their websites, before administering or utilizing any of the drugs, devices or materials mentioned in this book. This book does not indicate whether a particular treatment is appropriate or suitable for a particular individual. Ultimately it is the sole responsibility of the medical professional to make his or her own professional judgements, so as to advise and treat patients appropriately. The authors and publishers have also attempted to trace the copyright holders of all material reproduced in this publication and apologize to copyright holders if permission to publish in this form has not been obtained. If any copyright material has not been acknowledged please write and let us know so we may rectify in any future reprint.

Except as permitted under U.S. Copyright Law, no part of this book may be reprinted, reproduced, transmitted, or utilized in any form by any electronic, mechanical, or other means, now known or hereafter invented, including photocopying, microfilming, and recording, or in any information storage or retrieval system, without written permission from the publishers.

For permission to photocopy or use material electronically from this work, please access www.copyright.com (<http://www.copyright.com/>) or contact the Copyright Clearance Center, Inc. (CCC), 222 Rosewood Drive, Danvers, MA 01923, 978-750-8400. CCC is a not-for-profit organization that provides licenses and registration for a variety of users. For organizations that have been granted a photocopy license by the CCC, a separate system of payment has been arranged.

Trademark Notice: Product or corporate names may be trademarks or registered trademarks, and are used only for identification and explanation without intent to infringe.

Visit the Taylor & Francis Web site at
<http://www.taylorandfrancis.com>

and the CRC Press Web site at
<http://www.crcpress.com>

Contents

Foreword	ix
Preface	xi
Acknowledgments	xiii
Illustration credits	xv
1 Epidermolysis bullosa	1
Definition	1
Epidemiology	2
Epidermolytic epidermolysis bullosa	2
Junctional epidermolysis bullosa	8
Dermolytic epidermolysis bullosa	14
Kindler syndrome	20
2 Acantholytic diseases	23
Darier disease	23
Hailey–Hailey disease	27
3 Ichthyoses	31
Non-syndromic ichthyoses	31
Autosomal recessive congenital ichthyoses	36
Keratinopathic ichthyoses	46
Loricrin keratoderma	54
KLICK syndrome	54
Erythrokeratoderma variabilis	56
Progressive symmetric erythrokeratoderma	57
Pityriasis rotunda	59
Ichthyosis cribriformis	61
Peeling skin syndromes	62
Keratolytic winter erythema	64
Syndromic ichthyoses	65
Other syndromic ichthyoses	78
4 Palmoplantar keratodermas	89
Epidermolytic palmoplantar keratoderma	89
Keratoderma hereditaria mutilans	91
Loricrin keratoderma	93
Greither disease	94
Olmsted syndrome	95
Papillon–Lefevre syndrome	97
Huriez syndrome	98
Mal de Meleda	100
Punctate palmoplantar keratoderma	102
Striate keratoderma	104
Richner–Hanhart syndrome	105

Painful callosities	107
Pachydermoperiostosis	108
Acrokeratoelastoidosis	109
Naxos–Carvajal syndromes	110
Cole disease	112
Palmoplantar keratoderma-congenital alopecia syndrome	114
5 Other disorders of keratinization	115
Porokeratoses	115
Kyrle’s disease	118
Pityriasis rubra pilaris	120
6 Poikilodermas and aging syndromes	123
Disorders of DNA repair	123
Aging syndromes	134
Laminopathies	139
7 Hair diseases	145
Marie–Unna hypotrichosis	145
Hypotrichosis simplex of the scalp	146
Alopecia areata	147
Ulerythema ophryogenes	148
Triangular alopecia	150
Hypotrichosis with juvenile macular dystrophy	151
Localized hypotrichosis	152
Hereditary hypotrichosis and recurrent skin vesicles	152
Woodehouse–Sakati syndrome	153
Hypertrichosis congenita	155
Ambras syndrome	156
Localized hypertrichosis	158
Zimmermann–Laband syndrome	159
Monilethrix	160
Pili annulati	162
Pili torti	163
Woolly hair	165
Uncombable hair syndrome	166
Silvery hair syndrome	167
Menkes syndrome	169
Atrichia with papular lesions	171
Loose anagen syndrome	172
8 Nail disorders	173
Pachyonychia congenita	173
Nail–patella–elbow syndrome	176
Twenty-nail dystrophy	177
Malalignment of the great toenails	178
Leukonychia	179
Pterygium inversum of nails	180
Iso–Kikuchi syndrome	181
9 Sebocystomatosis	183
Sebocystomatosis	183
10 Oral mucosa	185
White sponge hyperplasia of the mucosa	185
Oral–facial–digital syndrome type I	186
11 Neurocutaneous syndromes	189
Neurofibromatosis type 1	189
Noonan syndrome	200

Cardio–facio–cutaneous syndrome	201
Costello syndrome	202
LEOPARD syndrome	204
Neurofibromatosis type 2	206
Tuberous sclerosis	208
12 Epidermal nevi and epidermal nevus syndromes	217
Introduction	217
Epidermal nevi and related syndromes	217
Phakomatosis pigmentokeratolica	227
Waxy keratosis	230
PENS syndrome	232
PEODDN	235
Nevoid follicular mucinosis	237
CHILD syndrome	238
13 Ectodermal dysplasias and related disorders	241
Ectodermal dysplasias	241
Hypohidrotic ED	241
p63-related ectodermal dysplasias	248
Tricho–dento–osseous syndrome	252
Witkop syndrome	254
Ellis–van Creveld–Weyers acrofacial dysostosis complex	255
Nectinopathies	256
Connexins-related syndromes	258
Ectodermal dysplasia–skin fragility syndrome	263
Pure hair–nail ectodermal dysplasia	264
Trichorhinophalangeal syndrome	266
Allgrove syndrome	267
Incontinentia pigmenti	269
Goltz syndrome	274
MIDAS syndrome	277
Naegeli–Franceschetti syndrome	278
X-linked reticulate pigmentary disorder with systemic manifestations (XLRPD)	280
14 Disorders of connective tissue	283
Ehlers–Danlos syndromes	283
Cutis laxa syndromes	294
Pseudoxanthoma elasticum	299
Urbach–Wiethe disease	302
Marfan syndrome	304
Loeys–Dietz syndrome	306
Arterial tortuosity syndrome	308
Stickler syndrome	309
Connective tissue nevi	310
Buschke–Ollendorff syndrome	312
Elastosis perforans serpiginosa	313
Michelin tire baby	314
Juvenile hyaline fibromatosis	315
Cutaneous mastocytosis	317
Cutaneous leiomyomatosis	318
Dermochondrocorneal dystrophy	319
GNAS-related syndromes: osteoma (osteomatosis) cutis, progressive osseous heteroplasia, Albright's hereditary osteodystrophy	321
Cutis verticis gyrata	323
15 Fatty tissue anomalies	325
Launois–Bensaude syndrome	325
Total lipodystrophy	326

Partial lipodystrophy	328
Lipomas, familial multiple lipomatosis and nevus lipomatosus	329
16 Aplasia cutis	331
Aplasia cutis	331
Adams–Oliver syndrome	335
17 Disorders of pigmentation	337
Oculocutaneous albinisms	337
X-linked ocular albinism	343
Hermansky–Pudlak syndrome	344
Cross syndrome	346
Hypomelanosis of Ito	347
Piebaldism	348
Waardenburg syndrome	350
McCune–Albright syndrome	351
Linear and figured hypo- and hyper-pigmented nevi	353
Melanocytic nevi and related syndromes	356
Segmental lentiginosis	358
Ota nevus	361
Cutis tricolor	362
Dyschromatosis symmetrica hereditaria	364
18 Vascular disorders	365
Fast-flow malformations	365
Slow-flow malformations	369
Other syndromes with prominent vascular signs	376
Lymphatic malformations and lymphedema syndromes	390
Generalized cyanosis, phlebectases and soft skin syndrome	393
Hemangioma syndromes	395
CADASIL	397
19 Metabolic diseases	399
Porphyria cutanea tarda and hepatoerythropoietic porphyria	399
Erythropoietic protoporphyria	402
Congenital erythropoietic porphyria	404
Hereditary coproporphyria and harderoporphyria	407
Variegate porphyria	409
Acrodermatitis enteropathica	410
Fabry disease	412
Sea-blue histiocytosis	414
Cerebrotendinous xanthomatosis	416
Prolidase deficiency	418
Methylmalonic aciduria	419
Alkaptonuria	421
20 Complex malformative syndromes with distinctive cutaneous signs	423
Rubinstein–Taybi syndrome	423
Cornelia de Lange syndrome	425
Cohen syndrome	427
Branchio–oculofacial syndrome	428
Barber–Say syndrome	430
Turner syndrome	432
Down syndrome	434
Pallister–Killian syndrome	434
Encephalocraniocutaneous lipomatosis	436
GAPO syndrome	438
Cantu syndrome	439
Apert syndrome	441

H syndrome	442
Poland syndrome	444
Kabuki syndrome	445
Primary intestinal lymphangiectasia	447
Congenital insensitivity to pain	448
Primary cutaneous amyloidosis	450
Frank–Ter Haar–Borrone syndrome	451
Familial comedones	453
21 Immunodeficiency disorders	455
Primary immunodeficiency syndromes	455
Ataxia–telangiectasia	455
Chediak–Higashi syndrome	458
Cartilage–hair hypoplasia	459
Chronic granulomatous disease	460
Chronic mucocutaneous candidiasis	461
APECED syndrome	462
Hyper-IgE syndromes	463
Hereditary angioedema	465
Omenn syndrome–severe combined immunodeficiencies	466
Common variable immunodeficiency	468
Wiskott–Aldrich syndrome	469
Immunoglobulin deficiencies	470
Cyclic neutropenia	472
Leukocyte adhesion deficiencies	473
DiGeorge syndrome	473
Fanconi anemia	474
22 Autoinflammatory diseases	477
Familial chilblain lupus	477
Aicardi–Goutières syndrome	479
Monogenic autoinflammatory diseases	481
23 Overgrowth syndromes	485
Proteus syndrome	485
CLOVES syndrome	487
Beckwith–Wiedemann syndrome	489
CLAPO syndrome	490
Klippel–Trénaunay syndrome	491
Macrocephaly–capillary malformation syndrome	491
24 Genodermatoses related to malignancy	493
Basal cell carcinoma syndrome	493
Constitutional mismatch repair-deficiency syndromes	496
PTEN hamartoma syndrome	498
Gardner syndrome	501
Bloom’s syndrome	503
Howel–Evans syndrome	504
Multiple endocrine neoplasia syndromes	505
Peutz–Jeghers syndrome	507
Birt–Hogg–Dubé syndrome	509
Carney complex	511
Bazex–Dupré–Christol syndrome	512
Epidermodysplasia verruciformis	514
Brooke–Spiegler syndrome	515
Progressive mucinous histiocytosis	517
Degos disease	518
Rombo syndrome	520

25	Cutaneous mosaicism	521
	Definition	521
	Pattern of clinical presentation of mosaicism	521
	The phenomenon of twin-spots	527
	Mechanisms of inheritance of mosaicism	529
26	Genodermatoses in dark skin	535

Foreword

Recent years have witnessed dramatic advances in our understanding of the biological foundations of inherited skin diseases. These new data are not only profoundly changing the way we diagnose, classify and manage genodermatoses, they are also raising many questions regarding the best way to teach regarding these complex disorders. In a time when genes and genetic mechanisms are playing an increasingly more prominent role in the definition of clinical entities and in their treatment (as they often predict therapeutic responses), clinical aspects of the medical evaluation process should not be overlooked. In fact, the modern diagnostic process very often requires the physician to be able to form links between clinical data and molecular features.

This is why we should applaud and congratulate Prof. Gianluca Tadini for bringing to us, experts and trainees alike, a new edition of the legendary *Atlas of Genodermatoses*. This comprehensive and, at the same time, very focused book is likely to

become, like its predecessor, a prerequisite for anyone struggling with a difficult case or wishing to expand his or her knowledge in genodermatology.

Making a diagnosis of a genetic skin disease is always a very challenging moment and a sometimes difficult task for a dermatologist. Genodermatoses are mostly rare diseases, and consequently, most professionals have little experience with these diseases. This unique collection of cases assembled patiently, over the course of years, by the late Ruggero Caputo and by Gianluca Tadini provides an unsurpassed overview of the major genodermatoses encountered in our daily practice, even if only on rare occasions. The new edition of the *Atlas of Genodermatoses* will remain, as in the past, a unique and unmatched adjunct diagnostic tool in dermatology and related medical disciplines.

Eli Sprecher
Tel Aviv, Israel

Preface

After 10 years, a second edition of our atlas is born!

The heritage of Ruggero Caputo is still alive in our hearts and we dedicate our three-years' efforts to his memory.

Many changes in clinical pattern, classification and genetics have occurred during this time.

However, the general layout of the atlas remains the same—brief captions, a concise text accompanied by relevant bibliographic references, and brief notes on management are the key core.

Many new classifications, accepted worldwide, have been included together with pathway schemes in order to better understand the pathogenic mechanisms of the diseases.

We have featured the works of contributors from all over the world who enriched this atlas

with figures of best cases that we were not able to see in our department. This means that this second edition must be considered a *consortium* of authors.

The picture contributions are specifically acknowledged in the *Photographic References* section. Unfortunately, for few diseases and for different reasons, we were not able to collect figures and, for them, the reader will find a concise text with bibliographic references.

We hope that our work may help students, trainees, and colleagues show interest in genodermatology.

Genetic data of each represented patient are available upon request at: gtadinicmce@unimi.it

Acknowledgments

First of all, we dedicate the atlas to the patients and their families.

We are grateful to our colleague Federica Dassoni for the outstanding pictures.

We also acknowledge all our colleagues from Italy and outside who have generously provided us with their *scientific friendship* and, in particular, Eli Sprecher (Tel Aviv, Israel), Maurice van Steensel (Maastricht, the Netherlands), Peter Itin (Basel, Switzerland), Cristina Has and Judith Fisher (Freiburg, Germany), Ramon Grimalt (Barcelona, Catalunya), Antonio Torrelo and Angela Hernández-Martin (Madrid, Spain), John McGrath (London, England), Vinzenz Oji and Heiko Traupe (Heidelberg, Germany), Marcel Jonkman (Groningen, the Netherlands), Smail Hadj-Rabia and Christine Bodemer (Paris, France), and Adrián-Martín Pierini (Buenos Aires, Argentina).

A special thanks to Susan Huson (Manchester, England), Eric Legius and Hilde Brems (Louvain, Belgium), Bruce Korf (Birmingham, Alabama, USA), and Dave Viskochill (Salt Lake City, Utah, USA) for the *brainstorming* on Neurofibromatosis 1 paragraph.

Not forgetting our Italian friends, specially, Mauro and Andrea Paradisi, Maya El Hachem,

Andrea Diociauti, Giovanna Zambruno and Daniele Castiglia, Marco Castori and Francesco Brancati (Rome), Iria Neri and Annalisa Patrizi (Bologne), Michele Callea (Triest), Marina Colombi and Alessandro Plebani (Brescia), Lucia Restano, Stefano Cambiaghi, and Riccardo Cavalli (Milan).

We also wish to thank all the colleagues from the Department of Dermatology of Milan with whom we shared expertise and constructive discussions and the entire staff of the Center for Inherited Cutaneous Diseases of the University of Milan: Elisa Faure, Luisa C. Rossi, Francesca Santagada, and Elena Colombo.

Finally, we extend a very special thanks to Francesca Besagni from Parma, Italy and Maria Pia Boldrini from Cordoba, Argentina, who, with their grace and brightness, supported us during these years.

Gianluca Tadini
Michela Brena
Carlo Gelmetti
Lidia Pezzani

Illustration credits

The authors are grateful to the following colleagues for their kind permission to reproduce their illustrations in the *Atlas*:

- Dr. Bernard Ackerman, New York University, New York, USA: 1.59, 1.60, 3.63, 11.57, 11.59, 11.64, 11.75, 13.82, 14.68, 17.56.
- Professor William Bacon, Department of Dentofacial Orthopedics, University of Strasbourg, Strasbourg, France: 20.32, 20.33.
- Dr. Samantha Berti and Dr. Giordana Coronella, Division of Dermatology, Department of Surgery and Translational Medicine, University of Florence, Florence, Italy: 12.29.
- Dr. Francesca Besagni, Dermatology Unit, University of Parma, Parma, Italy: 4.11, 4.12.
- Dr. Gianfranco Biolcati, Porphyria Centre, San Gallicano Institute, San Gallicano Hospital, Roma, Italy: 19.16, 19.17, 19.24, 19.26, 19.27, 19.56, 19.58, 19.59.
- Dr. Claudine Blanchet-Bardon, Hôpital S. Louis, Paris, France: 3.71, 4.10, 4.30, 4.31, 4.32, 4.35, 4.36, 4.37, 4.39, 4.42, 4.43, 4.44, 4.45, 4.57, 5.8, 5.9, 7.50, 7.51, 11.39, 11.40, 13.54, 13.59, 13.61, 13.62, 24.41, 24.42, 24.43.
- Dr. Valeria Boccaletti, Dermatology Unit, University of Parma, Parma, Italy: 3.152, 12.34.
- Dr. Vinicio Boneschi, Department of Dermatology, University of Milan, Milan, Italy: 4.38, 12.22, 12.58, 12.63, 12.67, 12.68, 14.86, 24.13, 24.14, 24.15, 24.23, 24.27.
- Professor Giovanni Borroni, Department of Dermatology, University of Pavia, Pavia, Italy: 20.19, 20.20, 20.23.
- Dr. Mariangela Bosoni, Department of Pediatrics, Sacco Hospital, University of Milan, Milan, Italy: 14.59, 14.60.
- Dr. Lucia Brambilla, Department of Dermatology, University of Milan, Milan, Italy: 4.38, 24.13, 24.14, 24.15, 24.23, 24.27.
- Professor Hugo Cabrera and Dr. Patricia Della Giovanna, Department of Dermatology, University of Buenos Aires, Argentina: 14.85, 19.50, 19.51, 19.52, 19.53, 19.54.
- Dr. Michele Callea, Institute for Maternal and Child Health—IRCCS “Burlo Garofolo,” Trieste, Italy: 10.7, 11.24, 13.3, 13.13, 13.14, 13.17, 13.18, 13.19, 14.23.
- Dr. Stefano Cambiaghi, Pediatric Dermatology Unit, University of Milan, Milan, Italy: 7.44, 17.32.
- Dr. Marco Castori, Division of Medical Genetics, Department of Molecular Medicine, Sapienza University, San Camillo-Forlanini Hospital, Rome, Italy: 7.21, 7.22, 7.23, 7.24, 13.23, 13.24, 14.11, 14.33, 20.34.
- Dr. Riccardo Cavalli, Pediatric Dermatology Unit, University of Milan, Milan, Italy: 18.82, 18.85, 18.86.
- Professor Marina Colombi, Department of Genetic, University of Brescia, Brescia, Italy: 14.1, 14.8, 14.9, 14.10, 14.12, 14.13, 14.14, 14.16, 14.17, 14.28, 14.29, 14.49, 14.51, 14.52, 14.53, 14.54, 14.55, 14.56, 14.57, 14.58.
- Professor Bruno Dallapiccola, Scientific Director, Bambino Gesù Children’s Hospital, Rome, Italy: 7.17, 7.18.
- Dr. Federica Dassoni, Department of Dermatology, University of Milan, Milan, Italy: 6.5, 6.6, 11.35, 11.65, 12.1, 12.8, 14.74, 17.11, 17.12, 17.49, 18.13, 18.15, 18.16, 18.17, 18.24, 18.68, 18.69, 18.71, 19.55, 19.57, 21.43, 23.9, 23.12, 24.28, 25.27, 25.35, 26.1–26.31.
- Dr. Anja De Moor, Department of Dermatology, University of Antwerp, Belgium: 6.49, 6.50, 6.51.
- Dr. Enzo Di Iorio and Dr. Paolo Raffa, The Veneto Eye Bank Foundation, Venice, Italy: 13.28.
- Dr. Andrea Diociaiuti, Dermatology Unit, Bambino Gesù Children’s Hospital, Rome, Italy: 1.13, 3.49, 3.153.

- Professor Robin Eady, Department of Dermatology, St. John's Institute of Dermatology, King's College, London, UK: 13.63, 13.64, 13.65.
- Dr. Maya El Hachem, Dermatology Unit, Bambino Gesù Children's Hospital, Rome, Italy: 3.147, 3.148.
- Dr. Silvia Esposito and Dr. Veronica Saletti, Istituto Neurologico Besta, Milan, Italy: 11.51, 11.52, 11.53.
- Dr. Daniele Fanoni and Professor Emilio Berti, Department of Dermatology, University of Milan, Milan, Italy: 1.64, 20.44.
- Dr. Claudio Feliciani, Dermatology Unit, University of Parma, Parma, Italy: 24.9.
- Dr. Anna Belloni Fortina, Pediatric Dermatology Unit, University of Padova, Italy: 3.149, 18.81, 18.83.
- Dr. Michele Gaffuri, Otolaryngology Department, University of Milan, Milan, Italy: 14.48.
- Dr. Giulia Genoni, Neonatal Pathology, Novara Hospital, Novara, Italy: 3.133, 3.134, 3.135.
- Dr. Tommaso Gobello, Istituto Dermopatico dell'Immacolata, IDI, Rome, Italy: 12.18, 12.19.
- Dr. Massimo Gola, Allergological and Occupational Dermatology Unit, University of Florence, Florence, Italy: 6.45, 6.46.
- Professor Rudolph Happel, University Hospital, Marburg, Germany: 3.136, 3.137, 3.138, 3.140, 3.141, 3.142, 12.69, 12.70, 12.71, 17.63, 18.32, 18.33, 18.56, 25.21, 25.24.
- Professor Christina Has, Department of Dermatology, University Medical Center Freiburg, Freiburg, Germany: 1.16, 1.17.
- Professor Hans Christian Hennies, Center for Dermatogenetics, Division of Human Genetics, Medical University Innsbruck, Innsbruck, Austria: 3.43, 3.44.
- Professor Herbert Hönigsmann, Department of Dermatology, University of Wien, Wien, Austria: 6.2.
- Historical Archives of Istituto Neurologico Carlo Besta, Milan, Italy: 18.31, 21.1, 21.6.
- Dr. Michel Janier, Hôpital S. Louis, Paris, France: 4.56.
- Professor Marcel Jonkman, Department of Dermatology, University of Groningen, Groningen, the Netherlands: 1.12, 1.20, 1.21, 1.33, 1.34, 1.65, 25.37.
- Dr. Ariana Kariminejad, Kariminejad-Najmabadi Pathology and Genetics Center, Shahrak Gharb, Tehran, Iran: 1.42, 1.43, 1.44.
- Dr. Merel Klaassens, Pediatric Intensive Care Unit, Maastricht University Medical Center, Maastricht, the Netherlands: 14.21, 14.22.
- Dr. Pablo Lapunzina, Section of Medical and Molecular Genetics, Instituto de Genética Médica y Molecular, Hospital Universitario La Paz, Autónoma University of Madrid, Madrid, Spain: 23.10, 23.11, 23.13, 23.14.
- Dr. Hiram Larangeira de Almeida Jr., Departments of Dermatology at Santa Casa de Porto Alegre, Pelotas, Brazil: 3.96, 3.97, 3.98.
- Professor Lidia Larizza, Division of Medical Genetics, San Paolo School of Medicine, University of Milan, Milan, Italy: 6.9, 6.10.
- Professor Margarita Larralde and Dr. Maria Pia Boldrini, Pediatric Dermatology Department, Hospital Ramos Mejía, Buenos Aires, Argentina: 6.24, 6.25, 12.30, 12.31.
- Dr. Wiebke Ludwig-Peitsch, Department of Dermatology, University Medical Center Mannheim, Mannheim, Germany: 4.64, 4.65.
- Dr. Luisa Lunardon, Department of Dermatology, University of Milan, Milan, Italy: 12.11, 18.84.
- Dr. Siranoush Manoukian, Institute of Cancer, Milan, Italy: 24.29, 24.30, 24.31.
- Dr. Angelo Valerio Marzano, Department of Dermatology, University of Milan, Milan, Italy: 22.11, 22.14, 22.15.
- Professor José Maria Mascarò, Department of Dermatology, Hospital Clinic, Barcelona, Spain: 1.30, 19.1.
- Professor John McGrath, Department of Dermatology, St. John's Institute of Dermatology, King's College, London, UK: 1.18, 1.19, 13.63, 13.64, 13.65.
- Dr. Bodo Melnik, Department of Dermatology, Environmental Medicine and Health Theory, University of Osnabrück, Germany: 20.35, 20.36.
- Dr. Laura Milazzo, Department of Biomedical and Clinical Sciences L Sacco, L. Sacco Hospital, University of Milan, Milan, Italy: 20.43.
- Dr. Arti Nanda, As'ad Al-Hamad Dermatology Center, Al-Sabah Hospital, Kuwait City, Kuwait: 7.12, 7.13.
- Professor Kenji Naritomi, Graduate School of Medicine, University of Okinawa, Nishihara, Okinawa, Japan: 25.15.
- Dr. Iria Neri, Department of Dermatology, S. Orsola-Malpighi Hospital, Bologna, Italy: 3.143, 3.144, 3.145, 15.9, 22.16, 24.8, 24.49, 24.50.
- Professor Paolo Nucci, Ophthalmology Department, San Giuseppe Hospital, Milan, Italy: 13.88, 13.89, 17.6, 17.17.
- Professor Enrico Nunzi, Department of Dermatology, University of Genoa, Italy: 17.9, 17.10.
- Dr. Laura Pantaleoni, Istituto Neurologico Besta, Milan, Italy: 18.50, 18.51, 18.52.
- Dr. Andrea Paradisi, Health Services Research Unit, Istituto Dermopatico dell'Immacolata, IDI, Rome, Italy: 4.66, 4.67, 4.68, 12.25, 12.26, 12.27, 14.45, 24.18, 24.22, 24.25, 24.26.

- Dr. Mauro Paradisi, Pediatric Dermatology, Istituto Dermopatico dell'Immacolata, IDI, Rome, Italy: 4.66, 4.67, 4.68, 6.7, 6.8, 6.33, 6.42, 12.35, 13.44, 13.45, 13.46, 14.45, 18.73.
- Professor Annalisa Patrizi, Department of Dermatology, University of Bologna, Bologna, Italy: 7.7, 7.8, 7.52, 20.16, 20.17, 20.18.
- Professor Adrián-Martín Pierini, Dermatology Service, Hospital de Pediatría Juan P. Garrahan, Buenos Aires, Argentina: 7.48, 21.9, 21.11, 21.12, 21.14, 21.16, 21.27, 21.28, 21.34, 21.35, 21.38, 21.39, 21.42, 22.8, 23.6, 23.7, 23.8.
- Professor Mario Pippione, Department of Dermatology, University of Turin, Turin, Italy: 19.39, 19.40, 19.41.
- Professor Nelida Pizzi de Parra, Department of Dermatology, Universidad de Cuyo, Mendoza, Argentina: 8.19, 8.21.
- Professor Alessandro Plebani, Pediatrics Clinic, Spedali Civili di Brescia, University of Brescia, Brescia, Italy: 21.5, 21.7, 21.10, 21.15, 21.19, 21.20, 21.21, 21.29, 21.31, 21.32, 21.33, 21.36, 21.37, 21.40, 21.41, 21.47, 22.9, 22.10.
- Dr. Attilio Pocchini, Department of Dermatology, University of Milan, Milan, Italy: 20.53.
- Dr. Giulia Pomerio, Terapia Intensiva Neonatale-Neonatalogia, Ospedale S. Croce e Carle, Cuneo, Italy: 3.48.
- Dr. Pawinee Rerknimitr, Dermatology Unit, Department of Medicine, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand: 20.57, 20.58.
- Dr. Lucia Restano, Pediatric Dermatology Unit, University of Milan, Milan, Italy: 12.55, 12.56.
- Professor Franco Rongioletti, Department of Health Sciences, DISSAL, University of Genoa, Genoa, Italy: 6.40.
- Professor Ramon Ruiz-Maldonado, University of Mexico City, Mexico, Hospital Distrito Federal, Mexico City, Mexico: 7.14, 7.15, 7.16, 7.46, 7.47, 21.8.
- Dr. Jorge L. Sanchez, Private Practice, Hato Rey, San Juan, Puerto Rico: 17.18.
- Dr. Paolo Sbraccia and Professor Giuseppe Novelli, Department of Internal Medicine and Department of Biopathology and Diagnostic Imaging, University of Rome "Tor Vergata," Rome, Italy: 6.52, 6.53.
- Dr. Sylvia Schauder, Department of Dermatology, University of Göttingen, Germany: 12.12.
- Dr. Carmelo Schepis, Department of Dermatology, Istituto Malattie Rare, Oasi Troina, Italy: 11.43, 17.33.
- Professor Holm Schneider, German Competence Centre for Children with Ectodermal Dysplasias, Department of Pediatrics, University of Erlangen-Nürnberg, Erlangen, Germany: 13.15.
- Dr. Angelo Selicorni, Pediatric Genetic Clinic Unit, San Gerardo Hospital, Monza, Italy: 11.37, 13.70, 14.50, 20.5, 20.6.
- Dr. Jan Cezary Sitek, Department of Dermatology, Oslo University, Oslo, Norway: 3.104, 3.105.
- Professor Eli Sprecher, Department of Dermatology, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel: 3.45, 3.99, 3.118, 3.119, 3.151, 3.154, 7.9.
- Professor Omar Boudghene Stambouli, School of Medicine Aboubakr Belkaid, Tlemcen, Algeria: 13.48, 13.49, 13.50.
- Dr. Mariam Tajir, Department of Medical Genetics, University of Rabat, Rabat, Morocco: 14.18, 14.19, 14.20.
- Professor Yasushi Tomita, Department of Dermatology, Nagoya University Graduate School of Medicine, Showa-Ku, Japan: 17.65, 17.66.
- Professor Antonio Torrelo, Department of Dermatology, Hospital Infantil Universitario del Niño Jesús, Madrid, Spain: 11.79.
- Dr. Antonella Tosoni and Dr. Manuela Nebuloni, Pathology Unit, L. Sacco Hospital, University of Milan, Milan, Italy: 3.161, 3.162, 18.87, 20.52.
- Professor Antonella Tosti, Department of Dermatology, University of Bologna, Bologna, Italy: 4.59, 4.60, 4.62, 4.63, 7.50, 7.51, 8.9, 8.10, 8.11, 21.2, 21.3.
- Professor Maurice A.M. van Steensel, Department of Dermatology, Maastricht University Medical Center, Maastricht, the Netherlands: 13.20, 13.21, 13.22, 20.54, 20.55, 24.67, 24.68.
- Dr. Ana Vega, Fundación Pública Gallega de Medicina Xenómica-SERGAS, Grupo de Medicina Xenómica-USC, Santiago de Compostela, Spain: 3.41, 3.42.
- Dr. Francesco Viola, Department of Ophthalmology, University of Milan, Milan, Italy: 11.27, 11.28, 11.29.
- Dr. Giovanna Zambruno, Laboratory of Molecular and Cell Biology, Istituto Dermopatico dell'Immacolata, IDI, Rome, Italy: 3.61.
- Dr. Abraham Zlotogorski, Department of Dermatology, The Center for Genetic Diseases of the Skin and Hair, Hadassah Hebrew University Medical Center, Jerusalem, Israel: 20.37, 20.38.

CHAPTER 1

Epidermolysis bullosa

DEFINITION

Epidermolysis bullosa (EB) consists of a heterogeneous group of mechanobullous diseases due to mutations on at least 17 different genes.

Table 1.1 gives a classification of hereditary epidermolysis bullosa, based on the last contribution of J.D. Fine and Coworkers.

As can be seen in the literature, the denominations *simplex* and *dystrophic* are commonly used, but we prefer to define EB regarding simply the site of the cleavage, abandoning the denomination of *simplex* and *dystrophic* that are, in our opinion, aspecific; i.e., we refuse to call *simplex* a group of

Table 1.1 Classification of hereditary epidermolysis bullosa (EB)

Type	Subtype	Mutated protein	Gene defect
EEB	EEB-generalized	Keratin 5, keratin 14	KRT5, KRT14
	EBS-MP	Keratin 5	p.P25L mutation (KRT 5)
	EBS-MCE	Keratin 5	c.1649delG mutation (K5)
	EEB-MD	Plectin	PLEC1
	EEB-Ogna subtype	Plectin	PLEC1
	EEB-PA	Plectin	PLEC1
	EEB-exophilin 5	Exophilin-5	EXPH5
	EEB-BP230 related	Dystonin	DST
	EEB-lethal acantholytic	Desmoplakin, plakophilin	DSP, PKP1
	APSS	Transglutaminase 5	TGM5
JEB	JEB-severe generalized	Laminin 5 ^a	LAMA3, LAMB3, LAMC2
	JEB-generalized intermediate	Laminin 5, collagen type XVII (BPAG2)	LAMA3, LAMB3, LAMC2, COL17A1
	JEB-PA ^b	Integrin $\alpha 6$ - $\beta 4$ ^c	ITGA6, ITGB4
	LOC	Laminin $\alpha 3$ gene ^d	LAMA3A
DEB	JEB-RR	Integrin $\alpha 3$	ITGA3
	DDEB	Collagen type VII	COL7A1
	RDEB	Collagen type VII	COL7A1
KINDLER		Kindlin-1	KIND1 (FERMT1)


EEB, epidermolytic EB; JEB, junctional EB; DEB, dermolytic EB; DDEB, dominant dermolytic EB; EBS-MP, EBS with mottled pigmentation; EBS-MCE, EBS with migratory mircinate erythema; EEB-MD, EEB with muscular dystrophy; EEB-PA, EEB with pyloric atresia; APSS, acral peeling skin syndrome; JEB-PA, JEB with pyloric atresia; LOC, Laryngo-onycho-cutaneous syndrome; JEB-RR, JEB with respiratory and renal involvement; DDEB, dominant dermolytic EB; RDEB, recessive dermolytic EB.

^a Laminin 5 is a macromolecule composed of three distinct ($\alpha 3$, $\beta 3$, $\gamma 2$) laminin chains; mutations in any of the encoding genes result in a JEB phenotype.

^b Some cases of EB associated with pyloric atresia may have intraepidermal cleavage or both intralamina lucida and intraepidermal clefts.

^c $\alpha 6$ - $\beta 4$ integrin is a heterodimeric protein; mutations in either gene have been associated with JEB-PA syndrome.

^d LAMA3 encodes three different isoforms, called $\alpha 3a$, $\alpha 3b1$, and $\alpha 3b2$; LOC is due to mutations in the $\alpha 3a$ protein.



Schematic drawing 1.1 Molecular basis of the different types of EB.

disorders in which there are potentially lethal variants. If the term *epidermolytic* does not fit to all subtypes of EB in which the site of cleavage is intraepithelial (basal or suprabasal), we prefer this term just in order to clearly underline the localization of blisters.

In analogy, we believe that in 2014 the term *dystrophic* is meaningless: we failed to find an exact definition of *dystrophy* that could fit with the subtypes of EB due to a genetic defect in COL7A1 gene.

Simplex and dystrophic are claimed to be maintained in order to avoid confusion in changing a well-established terminology, in other terms, they are used as *eponyms*. Curiously, in the last classification *eponyms* are waived and we agree totally on that.

Schematic drawing 1.1 shows the molecular basis of the different types of EB.

EPIDEMIOLOGY

In Italy there are more than 1000 EB patients among 60,000,000 inhabitants. Epidemiological data from the U.S. National Registry are superimposable.

EPIDERMOLYTIC (INTRAEPIDERMAL, INTRAEPITHELIAL, *SIMPLEX*) EPIDERMOLYSIS BULLOSA (EEB)

Genetics and pathogenesis

This group of EB is, in the vast majority, transmitted as an autosomal dominant trait, and encompasses about 40% of total EB patients. Fewer than 1% of cases are inherited recessively.

The site of cleavage is intraepidermal, with *basal* (cleavage within the basal layer) or *suprabasal* (cleavage in the upper layers).

Nine genes are involved in the pathogenesis of the disease, encoding, respectively, keratin 5 (K5), keratin 14 (K14), plectin (PLEC1), EXPH5 (Slac2b protein) and DST (*coiled-coil* domain of BP230), TGM5 (transglutaminase 5), DSP (desmoplakin), PKP1 (plakophilin), and JUP (plakoglobin).

Clinical cutaneous and extracutaneous findings

Localized, generalized, generalized severe, recessive (genes: K5, K14)

Bullae mainly involve palmoplantar sites (*localized*) (Figures 1.1 and 1.2) or be more widely distributed



Figure 1.1 Localized epidermolysis bullosa (EEB).



Figure 1.4 Generalized epidermolysis bullosa (EEB).



Figure 1.2 Localized epidermolysis bullosa (EEB).



Figure 1.5 Generalized severe epidermolysis bullosa (EEB).

in the napkin areas, face or folds (*generalized*) (Figures 1.3 and 1.4). Normally, the disease is not severe, except in some cases with a herpetiform jewel-like distribution and hemorrhagic bullae (*generalized severe*) (Figures 1.5 and 1.6). In these cases, blisters invariably also involve palmoplantar areas and are rapidly recurrent, causing palmoplantar keratodermas (Figures 1.7 and 1.8). A few fatal cases have been reported in the perinatal period due to the extreme severity of the disease. These



Figure 1.3 Generalized epidermolysis bullosa (EEB).



Figure 1.6 Generalized severe epidermolysis bullosa (EEB).



Figure 1.7 Generalized severe epidermolytic epidermolysis bullosa (EEB).



Figure 1.8 Generalized severe epidermolytic epidermolysis bullosa (EEB).



Figure 1.9 Generalized severe epidermolytic epidermolysis bullosa (EEB).

children reach milestones of physical development later, such as the ability to walk and run (and hence attend school), partly because of the palmoplantar lesions and partly because of the frequent oral lesions (Figure 1.9) that impair food consumption and may lead to anemia.

In these patients, nails are frequently absent (Figure 1.10) and alopecic areas may be detected as well as milia on the dorsa of the hands.



Figure 1.10 Generalized severe epidermolytic epidermolysis bullosa (EEB).

At around 8–10 years of age, the situation tends to improve, and in adulthood, EEB is restricted to occasional mechanically involved sites, such as the feet, elbows and knees.

Symptoms in all of the epidermolytic subtypes tend to worsen during the summer and in hot and humid weather.

In the few described EEB families with the *recessive mode of inheritance of K14 mutations* (1%), lesions are in general more severe (Figures 1.11 and 1.12) than in families with dominant inheritance. They may show severe anogenital lesions, post lesional nevi, ichthyotic plaques and focal palmo-plantar keratoderma.

Mottled pigmentation and migratory circinate erythema subtypes

Mottled pigmentation subtype (EBS-MP) (K5 gene): This subtype, due to a particular K5 gene mutation



Figure 1.11 Recessive epidermolytic epidermolysis bullosa (EEB).



Figure 1.12 Recessive epidermolytic epidermolysis bullosa (EEB).

(p.P25L), is characterized by a generalized clinical pattern with mottled and/or reticulate hyperpigmentation (Figure 1.13).

Migratory circinate erythema subtype (EBS-MCE) (K5 gene) shares hyperpigmented post-inflammatory lesions and generalized pattern with the former subtype. The peculiarity resides in slowly enlarging erythema and erosions with centrifugal course. This subtype is caused by a mutation c.1649delG in K5 gene (Figure 1.14).



Figure 1.13 Epidermolytic epidermolysis bullosa (EEB) mottled pigmentation subtype.



Figure 1.14 Epidermolytic epidermolysis bullosa (EEB) migratory circinate erythema subtype.

Plectin-related subtypes

EEB-muscular dystrophy: This is characterized by a clinical picture of generalized EB inherited recessively, with onset at birth and accompanied by a late-onset progressive muscular weakness (7–10 years) (Figure 1.15). Mucosal manifestations are clinically relevant, with different degrees of severity and with upper respiratory tract involvement with recurrent pneumonitis. In two cases, visceral involvement (esophagus, bladder) has been reported. Obviously, muscular dystrophy tends to overwhelm skin lesions regarding the course and prognosis of the disease.

EEB-ogna: In Norway, mutations of plectin gene have been found in a large group of families with dominant inherited generalized epidermolytic EB without signs of muscular involvement. These patients show mainly acral distribution of lesions and onychogryphosis.

EEB-pyloric atresia: Finally, plectin gene mutations cause in few pedigrees severe epidermolytic EB and concomitant pyloric atresia, heralded by polyhydramnios and premature delivery. Skin signs at birth are very severe with bullous lesions, aplasia-cutis-like areas and early fatal outcome. Only in one case skin signs improved with age but a single case of severe visceral involvement (trachea, esophagus,



Figure 1.15 EEB-muscular dystrophy.

urethral, and megacolon) have been reported. Nails and teeth may be involved. Malformed pinnae and nasal alae, joint contractures and cryptorchidism have been reported.

It must be remembered that a very similar clinical picture of severe epidermolytic EB associated with pyloric atresia is due to mutations of the genes encoding for the two subunits of integrin $\alpha 6\text{-}\beta 4$, causing the variant of junctional EB with pyloric atresia.

Early detection of pyloric defect and surgical treatment are mandatory as early as possible.

EXPH5-related epidermolytic EB

Four cases are described, three from the same Iraqi family and one from Germany.

The disease is inherited in an autosomal recessive pattern. The EXPH5 gene encodes Slac2b-exophilin-5 protein that is involved in intracellular protein transport and exosome secretion. The site of cleavage is within the basal keratinocyte layer.

The onset is characterized by extensive erosions on the arms, legs and thorax (Figures 1.16 and 1.17). Initial lesions are not followed by atrophy and scarring. Pigmentary changes may be visible. Adnexa are spared.



Figure 1.16 EXPH5-related epidermolytic EB.



Figure 1.17 EXPH5-related epidermolytic EB.



Figure 1.18 EXPH5-related epidermolytic EB.

The course is benign with trauma-induced small blisters–erosions with residual crusting at the extremities (Figure 1.18).

BP230-related EEB

Few cases are signaled in the literature.

BP230 or BPAG1-e is also known as the epithelial isoform of bullous pemphigoid antigen 1 and is one of the components of hemidesmosomes. The DST (dystonin) gene encodes the coiled-coil domain of BP230: Mutations of this gene have been found to cause a subset of EEB, leading to the loss of hemidesmosomal inner plaques and skin fragility.

The disease is transmitted as an autosomal recessive trait.

Onset is at birth, with lifelong, diffuse, spontaneous and trauma-induced blisters and erosions, mainly located at the ankles (Figure 1.19). Nails may be involved.



Figure 1.19 BP230-related EEB.

(Lethal) acantholytic EB

This form is characterized by extensive shedding of the epidermis at birth or shortly thereafter (Figure 1.20). Few pedigrees have been described, all invariably with fatal outcome. Total alopecia, nails and external ears malformation and associated cardiomyopathy were observed. This variant is due to mutations in DSP (desmoplakin) and PKP1 (plakophilin) genes. Desmoplakin, is the *leader* in the constitution of desmosomal structures in epithelia and heart. Desmoplakin *anchors* plakoglobin and plakophilin to form the desmosomal plaque. Ultrastructural analysis shows suprabasal cleavage with abnormal tonofilament insertion and rudimentary or absent desmosomal inner plaques.

A further subtype of EEB is denominated as *skin fragility syndromes* (SFS) and includes:

- Desmoplakin-deficiency: SFS-desmoplakin-SFS with wooly hair.
- Plakoglobin-deficiency: SFS-plakoglobin deficiency.
- Plakophilin-deficiency: SFS-ectodermal dysplasia syndrome (see Chapter 13).
- All three subtypes have generalized pattern, with erosions, crusts, and few blisters, involvement of nails bed, may have scalp abnormalities (hypotrichosis and wooly hair) and different degree of palmo-plantar keratoderma (focal, punctuate, or striate). Cardiomyopathy may also be present (see also Chapter 4).

Of note, *acral peeling skin syndrome*-transglutaminase 5-related is included, in the last classifi-



Figure 1.20 EEB acantholytic subtype.

cation, as a rare variant of suprabasal EB (see Chapter 3).

Finally, a further pedigree defined as *epidermolysis bullosa superficialis* is included in the last classification. Patients are described to be characterized by superficial erosions without blisters but with possible postinflammatory hypopigmentation.

Noteworthy, first described cases with this name turned to be a variant of dominant dermolytic EB (!). The causative gene of the recent proposed cases is unknown.

Laboratory findings

- Skin biopsies, taken at the peribullous areas, are necessary to perform immunofluorescence and/or immunohistochemistry that may reveal defect of expression of the different components.
- The second step is electron microscopy (EM) that demonstrates intraepidermal cleavage with cytolysis and clumping of tonofilaments in the basal layers. Based on the EM and DIF results, the further step is represented by molecular studies that are performed with blood samples or cultured keratinocytes, in order to detect mutations in the K5–K14 genes for major forms or the plectin gene for EEB with muscular dystrophy and the Ogná subtypes, plectin or $\alpha 6-\beta 4$ mutations for epidermolytic EB with pyloric atresia, DSP and PKP1 genes for acantholytic subtype; DSP, PKP1, and JUP genes for skin fragility syndromes.

Follow-up and therapy

- Fortunately, for the majority of patients, EEB does not represent an obstacle to a normal life. In contrast, the more severe patients (severe generalized subtype) have to be frequently checked during preschool age in order to maintain normal food intake and growth centiles.
- Antibiotic therapy and special dressing are required.
- Orthopedic advice is mandatory to assess devices and physiotherapy for normal walking and development.
- Acantholytic subtype may be lethal in the neonatal period. These patients require hospitalization in neonatal intensive care unit.

JUNCTIONAL EPIDERMOLYSIS BULLOSA (JEB)

Genetics and pathogenesis

Cleavage of JEB is intra-lamina lucida.

JEB is a heterogeneous subgroup of EB due to mutations in several genes encoding the major constituents of the hemidesmosomes, and represents usually fewer than 10% of EB patients.

The involved genes are the following:

- LAMA3, LAMB3, and LAMC2 genes (laminin 332 protein) for generalized severe (former Herlitz subtype), generalized intermediate and for the rare subtypes called *localized* and *inversa*
- LAMA3A (isoform alpha 3 chain) for LOC syndrome
- COL17A1 gene (collagen XVII protein) for generalized intermediate, localized, and *late onset* subtypes
- ITGA6 and ITGB4 genes (integrin $\alpha 6$ - $\beta 4$ protein) for JEB with pyloric atresia (lethal and non-lethal cases)
- ITGB4 is also involved in rare cases of localized subtype
- ITGA3 gene (integrin $\alpha 3$ subunit) for JEB with renal and respiratory involvement

Revertant mosaicism may be visible in JEB (Figure 1.21)

Clinical cutaneous and extracutaneous findings

Severe generalized (former Herlitz) JEB

The extreme severity of this disease is already noticeable at birth (Figure 1.22).

Bullae present spontaneously even with a gentle touch. After the eruption, blisters lose their roof and remain visible as erosions that do not heal (Figure 1.23). In particular, granulomatous and easily bleeding lesions (Figure 1.24) arise on such eroded epithelium.



Figure 1.21 Junctional epidermolysis bullosa (JEB).



Figure 1.22 Severe generalized JEB.



Figure 1.23 Severe generalized JEB.

The general condition is very poor, with characteristic laryngeal stridor and crying.

Pulmonary involvement is frequent, and recurrent, very severe episodes with bronchiolitis and pneumonia are detected and require permanent hospitalization in a neonatal pathology unit.

The oral mucosa is heavily involved as well as the mucosa of the upper respiratory tract. In contrast, the esophageal epithelium is less involved.

Nails are involved and are often absent. Enamel defects are present as well as the high risk to develop caries.



Figure 1.24 Severe generalized JEB.



Figure 1.25 Severe generalized JEB.

Characteristically, eroded lesions begin at the face, in the zygomatic areas (Figure 1.25) and can progressively reach large dimensions (Figures 1.26 and 1.27). Usually these patients die within the first two years of life (due to sepsis or upper respiratory tract occlusion) but some, rare, patients with generalized cutaneous and internal disease reach the age of 10–15 years.



Figure 1.26 Severe generalized JEB.



Figure 1.27 Severe generalized JEB.

Generalized intermediate JEB (former non-Herlitz subtypes)

This subgroup is composed of two distinct clinical pictures that diverge in terms of some particular aspects.

The first (related to a laminin 332 deficiency) has generalized involvement, and the bullae are smaller and tend to heal within days (Figures 1.28 and 1.29). Atrophic residual scarring is the rule. The nails are always involved and dystrophic. Oral mucosa is involved and there is a high proneness to caries. In particular, patients develop large ulcerated lesions on pretibial areas, due to the continuous recurrence of the bullae (Figures 1.30 and 1.31). There is a high risk of cancer in these areas (Figure 1.31). Sudden eruptions of small follicular blisters



Figure 1.28 Generalized intermediate JEB (laminin 332 deficiency).



Figure 1.29 Generalized intermediate JEB (laminin 332 deficiency).



Figure 1.30 Generalized intermediate JEB (laminin 332 deficiency).



Figure 1.31 Generalized intermediate JEB (laminin 332 deficiency).

are possible during adolescence (Figure 1.32), as well as the development of pigmented post-bullous lesions that, at the epidiascopic examination, are diagnosed as true melanocytic nevi (Figures 1.33 and 1.34). Life expectancy is reduced.

The second group (related to mutations on the COL17A1 gene) is characterized by generalized and severe involvement (Figures 1.35 through 1.37) with oral mucosa and very severe dental anomalies (Figure 1.37), and especially by male pattern-like alopecia that is visible in both sexes (Figure 1.38). The hands and feet are thin and long, with dystrophic or absent nails (Figure 1.39). Atrophic residual scarring is visible.

Despite the risk of squamous cell carcinomas (25%), in these patients the disease allows an almost normal life span.



Figure 1.32 Generalized intermediate JEB (laminin 332 deficiency).



Figure 1.33 Generalized intermediate JEB (laminin 332 deficiency).

JEB with pyloric atresia

Pregnancy may be complicated by polyhydramnios.

Patients are severely involved at birth (Figure 1.40) as in generalized severe JEB, and suddenly develop gastrointestinal symptoms such as intractable




Figure 1.34 Generalized intermediate JEB (laminin 332 deficiency).



Figure 1.35 Generalized intermediate JEB (COL17A1 mutations).

vomiting. X-rays without contrast demonstrate enlargement of the stomach (Figure 1.41). Duodenal or anal atresia, as well as genitourinary tract malformations, has been reported. Pyloric reconstruction is mandatory in the first days of life. In some patients, cutaneous involvement is not so deep, allowing the recanalized patient to reach a normal life span, but usually these babies die within the first months of life.

JEB-LOC subtype

Laryngo–onycho–cutaneous syndrome (LOC) is an autosomal recessive disease characterized by cutaneous erosions, severe nail involvement and exuberant formation of granulation tissue in the skin, larynx, and conjunctiva (Figures 1.42 through 1.44).



Figure 1.36 Generalized intermediate JEB (COL17A1 mutations).

This disorder is due to mutations in the laminin $\alpha 3$ gene (LAMA3) in which premature stop codon mutations cause the lethal (Herlitz) variant of JEB.

The same gene LAMA3 encodes three different isoforms, called $\alpha 3a$, $\alpha 3b1$, and $\alpha 3b2$.

LOC is due to mutations in the $\alpha 3a$ protein that is secreted exclusively by the basal cells of stratified epithelia.

JEB late-onset is included as a further rare subtype of JEB in the last classification of 2014. The onset may be during adulthood or later with diffuse lesions with milia, onychodystrophy, hyperhidrosis, and absent dermatoglyphs. Mucosal lesions and enamel defects may be present. This subtype is due to peculiar COL17A1 mutations.



Figure 1.37 Generalized intermediate JEB (COL17A1 mutations).



Figure 1.38 Generalized intermediate JEB (COL17A1 mutations).



Figure 1.41 JEB with pyloric atresia.



Figure 1.39 Generalized intermediate JEB (COL17A1 mutations).

JEB inversa is characterized mainly by the intertriginous distribution of skin lesions (Laminin 332 defect).

JEB localized is characterized by recurrence of blisters and erosion in localized areas of the skin (Laminin 332 defect).

JEB with respiratory and renal involvement is due to mutations (gain of glycosylation) of the ITGA3 gene, coding for alpha 3 integrin. In this rare



Figure 1.40 JEB with pyloric atresia.



Figure 1.42 JEB-LOC subtype.



Figure 1.43 JEB-LOC subtype.

Follow-up and therapy

- Neonatal pathology units for severely affected patients
- Antibiotics for pulmonary infections
- Local antiseptics for slowly healing lesions and advanced dressing for the medication of ulcers
- Specific dressing
- Periodic (3–6 months) day-hospital for general examination, especially for neoplastic transformation
- Psychological support for patients and families
- Surgery for pyloric obstruction



Figure 1.44 JEB-LOC subtype.

subtype, congenital nephrotic syndrome and severe respiratory distress with interstitial pneumopathy are associated to blisters and erosions, mainly located on buttocks and legs. Death is the rule within the first months of life due to the severe and untreatable kidney and pulmonary involvement.

Laboratory findings

- Direct immunofluorescence and electron microscopy to detect expression of targeted proteins and site of cleavage
- Molecular investigation to reveal mutations in the involved genes

DERMOLYTIC (*DYSTROPHIC*) EPIDERMOLYSIS BULLOSA

Genetics and pathogenesis

Cleavage of blisters is below the lamina densa, in the uppermost dermis.

Dermolytic EB can be inherited in both dominant and recessive fashion and account for more than a half of EB patients.

The underlying molecular defect is unique and is related to the COL7A1 gene, encoding for collagen type VII, the major constituent of the anchoring fibers. The wide spectrum of severity in dermolytic EB is determined by the type of mutation in the COL7A1 gene. Noteworthy, revertant mosaicism is visible in these patients (see Figure 1.65 below).

Clinical findings

Dominant inherited subtypes

Lesions are visible at birth and are related to friction areas, especially on the hands and feet, where fingers and nails are always involved.

Blisters invariably cause scars and milia (Figures 1.45 and 1.46). During infancy and childhood,

blisters are visible on the extensor surface of the hands, elbows, knees, and shoulders, where they heal and assume an onion-like appearance (Figure 1.47). Nails are seldom healthy and mucosae can be heavily affected, especially in the esophageal tract, where severe strictures are possible, often in sharp contrast with the scarce cutaneous involvement. Usually, fingers and toes are not affected by major cicatricial retractions (Figure 1.48). The former allopapuloid Pasini–Pierini variant defines only a particular healing pattern of these patients (Figure 1.49).



Figure 1.47 Dominant dermolytic epidermolysis bullosa.



Figure 1.45 Dominant dermolytic epidermolysis bullosa.



Figure 1.48 Dominant dermolytic epidermolysis bullosa.



Figure 1.46 Dominant dermolytic epidermolysis bullosa.



Figure 1.49 Dominant dermolytic epidermolysis bullosa.

To be defined as dominant, each dermolytic EB patient must have confirmation in the pedigree, in order to avoid the false parallelism *mild case = dominant, severe case = recessive* that, in the past, led to wrong genetic counseling.

Of note, in the last classification, *acral, localized, pretibial* and *nails only* subtypes are included as further dominant inherited variants.

Recessive inherited subtypes

In the current classification, two major forms are described as *severe-generalized* and *generalized*.

As previously described, the underlying different genetic defect in COL7A1 defines the clinical picture of the single patient, and theoretically these two types of recessive dermolytic EB may be considered to be a unique group of patients with a wide spectrum of phenotypes (Figures 1.50 through 1.58).

The 'generalized intermediate' subtype is defined by some related mutations leading to a *milder* phenotype, with generalized cutaneous involvement and esophageal strictures with or without cicatricial pseudosyndactyly of the hands and feet (Figures 1.50 and 1.51). Cutaneous-mucosal involvement and esophageal lesions allow the patients to grow following the lower centiles, with minor food intake problems (Figure 1.52). A certain degree of ocular involvement may be visible.

The *generalized severe* subtype defines patients that are often linked to homozygous premature stop codon mutations, leading to a phenotype



Figure 1.50 Recessive dermolytic epidermolysis bullosa, generalized-intermediate subtype.



Figure 1.51 Recessive dermolytic epidermolysis bullosa, generalized-intermediate subtype.



Figure 1.52 Recessive dermolytic epidermolysis bullosa, generalized-intermediate subtype.



Figure 1.53 Recessive dermolytic epidermolysis bullosa, generalized severe subtype.

characterized by generalized cutaneous blisters and erosions that, during early infancy, lead to retractive scars of the hands and feet (pseudosyndactyly), and, later, to retractions of the major joints of the arms and legs that cause, in adolescence, an almost complete inability to stand up correctly (Figures 1.53 through 1.57). The hands are deeply affected, and in extreme cases resemble a bag or a pouch (Figure 1.58).